AbbVie Inc. $ABBV Stock Purchased by Sepio Capital LP

Sepio Capital LP raised its stake in AbbVie Inc. (NYSE:ABBV) by 475.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 749,451 shares of the company’s stock after purchasing an additional 619,274 shares during the quarter. AbbVie comprises about 7.9% of Sepio Capital LP’s investment portfolio, making the stock its 2nd biggest position. Sepio Capital LP’s holdings in AbbVie were worth $196,049,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in ABBV. Strategic Planning Group LLC bought a new stake in AbbVie during the third quarter valued at $392,000. Ledyard National Bank lifted its position in AbbVie by 3.7% in the 3rd quarter. Ledyard National Bank now owns 17,706 shares of the company’s stock valued at $4,632,000 after purchasing an additional 626 shares during the last quarter. Seros Financial LLC boosted its stake in AbbVie by 4.1% during the 3rd quarter. Seros Financial LLC now owns 1,184 shares of the company’s stock valued at $310,000 after purchasing an additional 47 shares during the period. NBT Bank N.A. acquired a new stake in shares of AbbVie in the third quarter valued at approximately $12,884,000. Finally, Root Financial Partners LLC boosted its position in shares of AbbVie by 71.0% during the third quarter. Root Financial Partners LLC now owns 12,318 shares of the company’s stock worth $3,222,000 after buying an additional 5,115 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

AbbVie Stock Up 0.2%

Shares of ABBV traded up $0.47 during trading hours on Friday, reaching $285.66. The company’s stock had a trading volume of 4,625,678 shares, compared to its average volume of 5,199,403. The company has a 50 day moving average of $266.33 and a two-hundred day moving average of $241.77. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The firm has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a P/E/G ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the firm earned $2.97 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts forecast that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ABBV. Argus increased their price target on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Scotiabank raised their target price on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Guggenheim reissued a “buy” rating and issued a $288.00 price target on shares of AbbVie in a report on Friday, October 9th. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, Citigroup lifted their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $279.86.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.